Passage Bio (PASG)

Executive Summary

Passage Bio is a clinical-stage genetic medicines company pioneering one-time AAV gene therapies for rare monogenic CNS disorders. Its lead candidate, PBFT02, is in a Phase 1/2 trial (NCT04747431) for frontotemporal dementia caused by GRN mutations (FTD-GRN), with enrollment ongoing and estimated completion in 2031. The company is also advancing PBGM01 for GM1 gangliosidosis, targeting a high unmet need in pediatric neurodegenerative disease. Passage Bio's strategy leverages optimized capsid engineering to achieve broad CNS biodistribution, aiming to permanently alter disease trajectories. Despite a compelling scientific approach, Passage Bio faces significant clinical and financial risks. The stock has a low valuation (~$13M), reflecting early-stage pipeline and high development uncertainty. Near-term catalysts include interim safety and efficacy data from the PBFT02 trial, which could provide proof-of-concept for its gene therapy platform. The company may also announce the initiation of the GM1 gangliosidosis trial or seek strategic partnerships to extend its cash runway. Given its focused pipeline and high-risk profile, Passage Bio represents a speculative investment opportunity with potential upside if clinical data are positive.

Upcoming Catalysts (preview)

• Q1 2027Interim data from Phase 1/2 PBFT02 trial in FTD-GRN40% success
• Q2 2026Initiation of Phase 1/2 trial for PBGM01 in GM1 gangliosidosis60% success
• Q4 2026Partnership or financing announcement to extend cash runway50% success